AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biomira Initiates Phase II Pilot Study Of BLP25 Vaccine.
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- Biomira Inc. (BIOM, BRA) has initiated of a Phase II clinical trial evaluating BLP25 vaccine in patients with prostate cancer.
The study is designed to test active specific immunotherapy with BLP25 vaccine as a treatment for patients who have recurrent disease following radical prostatectomy for prostate cancer. The primary endpoint of the trial is to reduce or stabilize prostate-specific antigen (PSA) values in patients with rising PSA post-radical prostatectomy. PSA is believed to be a useful tumor marker that is associated with the presence of prostate cancer, and is used to monitor a patient's recurrence or progression. Immune response and safety will be measured as secondary endpoints.
The trial is expected to enroll approximately 20 patients. Patients will have undergone radical prostatectomy for treatment of prostate cancer at least six months prior to study entry. Under the lead investigator, Dr. Scott North, from the Alberta Cancer Board, Cross Cancer Institute in Edmonton, patients will receive a low dose of cyclophosphamide and then 1000 micrograms of BLP25 vaccine once a week for eight weeks. Patients may receive maintenance treatments every six weeks thereafter until completion of the trial. Patients will be evaluated for serum PSA status over a one-year period.
"This trial has been designed ...
- Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon.
- News wire article from: The America's Intelligence Wire December 18, 2008 700+ words
...we are grateful that Merck KGaA has recognized the knowledge...Serono, a division of Merck KGaA. "In addition, with...cancer, breast cancer, prostate cancer and colorectal cancer...cells expressing MUC1. Merck KGaA currently is conducting...
- Biomira and Merck KGaA Announce Phase III Theratope(R) Vaccine Trial Does Not...
- Press release article from: PR Newswire June 17, 2003 700+ words
...TSX:BRA) and Merck KGaA of Darmstadt, Germany...disease. Biomira and Merck KGaA are also collaborating...Phase II pilot study for prostate cancer patients. Results from...operating activities under Merck KGaA, in which the Merck...
- Techniclone Corporation and Merck KGaA Sign Agreement On Use of Tumor Necrosis...
- Press release article from: Business Wire October 23, 2000 700+ words
...TNT) technology with Merck KGaA of Darmstadt, Germany...pancreatic, liver and prostate cancer. "This license agreement...licensing agreement with Merck KGaA allows Techniclone to...without the permission of Merck KGaA. The deal is structured...
- Biomira and Merck KGaA announce Phase III Theratope vaccine trial does not meet...
- News wire article from: Asia Africa Intelligence Wire June 17, 2003 700+ words
...Press Release) Biomira Inc and Merck KGaA announced that the results from...in a Phase II pilot study for prostate cancer patients. Results from both of...approaches to cancer management. Merck KgaA of Darmstadt, Germany aims to...
- Encouraging Phase IIb findings for Merck KGaA/Biomira's cancer vaccine.
- Newspaper article from: Pharma Marketletter April 12, 2004 700+ words
...Biomira and Germany-headquartered Merck KGaA have released promising preliminary...peak sales of $200 million a year. Prostate cancer study The vaccine candidate has also...evaluated for its potential utility against prostate cancer. In a 16-patient pilot study in...
- A Report Covering Merck KGaA, Including Their Deals, Financial Information, and...
- Press release article from: Business Wire November 11, 2005 700+ words
...reports/c26873 ) has announced the addition of Merck KGaA Deals Briefing to their offering. Description Merck KGaA Deals briefing provides an in-depth view of the 83 deals made by Merck KGaA and its subsidiaries with 116 partnering companies...
- HUMAN GENOME SCIENCES, SMITHKLINE BEECHAM, AND MERCK KGaA SIGN GENOMICS...
- Press release article from: PR Newswire July 16, 1996 700+ words
...HGS), SmithKline Beecham (SB), and Merck KGaA of Darmstadt, Germany today announced...agreement for a collaboration in which Merck KGaA would pursue the discovery and development...June 2001. Through this collaboration, Merck KGaA joins HGS, SB, Takeda Chemical Industries...
- ImClone Systems and Merck KGaA Sign Development and Commercialization Agreement...
- Press release article from: Business Wire December 15, 1998 700+ words
...Systems Incorporated (NASDAQ: IMCL) and Merck KGaA (DAX: MRX GR) announced today that...Under the terms of the agreement, Merck KGaA receives the exclusive license to develop...for the commercial production of C225. Merck KGaA will fund clinical development outside...
- Federal Judge Enters Final Post-Judgment Orders In Favor Of Integra...
- Press release article from: Business Wire October 17, 2001 700+ words
...orders in favor of the plaintiffs and against Merck KGaA on the final post-judgment motions in the...LifeSciences I Ltd. and The Burnham Institute v. Merck KGaA. The Court denied Merck KGaA's motions for judgment as a matter of law...
- Merck KGaA Selects MDL's ISIS/Direct as the New Foundation of Their Research...
- Press release article from: Business Wire March 4, 2002 700+ words
...industry and academia, announced today that Merck KGaA has selected MDL's ISIS/Direct data...Direct will enable software developers at Merck KGaA to design and deploy sophisticated systems...In addition to managing reactions, Merck KGaA scientists using ISIS/Direct will be...
Source: HighBeam Research, Biomira Initiates Phase II Pilot Study Of BLP25 Vaccine.